In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affinivax, Inc.

http://affinivax.com/

Latest From Affinivax, Inc.

GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition

GSK has spotted an opportunity to challenge Pfizer’s blockbuster Prevnar franchise, but the potential of Affinivax’s platform has yet to be proven.

Commercial Companies

Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines

US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.

US FDA Performance Tracker Review Pathway

Affinivax's 24-Valent Pneumococcal Vaccine Targets Growing And Changing Market

A potential next-generation, 24-valent, pneumococcal vaccine in development by Affinivax and Astellas has shown strong immunogenicity in a Phase II study and is preparing to enter pivotal Phase III trials; if successful, it will target a growing market currently dominated by big pharma players.

Vaccines Clinical Trials

Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe. 

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register